Constitutive Activation of Tethered-Peptide/Corticotropin-Releasing Factor Receptor Chimeras
Constitutive activity, or ligand-independent activity, of mutant G protein-coupled receptors (GPCRs) has been described extensively and implicated in the pathology of many diseases. Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we present a ligand-depe...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS Vol. 97; no. 18; pp. 10277 - 10281 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
National Academy of Sciences of the United States of America
29-08-2000
National Acad Sciences National Academy of Sciences The National Academy of Sciences |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Constitutive activity, or ligand-independent activity, of mutant G protein-coupled receptors (GPCRs) has been described extensively and implicated in the pathology of many diseases. Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we present a ligand-dependent constitutive activation of a GPCR. A chimera in which the N-terminal domain of the CRF receptor is replaced by the amino-terminal 16 residues of CRF displays significant levels of constitutive activation. The activity, as measured by intracellular levels of cAMP, is blocked in a dose-dependent manner by the nonpeptide antagonist antalarmin. These results support a propinquity effect in CRF receptor activation, in which the amino-terminal portion of the CRF peptide is presented to the body of the receptor in the proper proximity for activation. This form of ligand-dependent constitutive activation may be of general applicability for the creation of constitutively activated GPCRs that are regulated by peptide ligands such as CRF. These chimeras may prove useful in analyzing mechanisms of receptor regulation and in the structural analysis of ligand-activated receptors. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Novo Nordisk A/S, DK-2880 Bagsværd, Copenhagen, Denmark. Contributed by Wylie W. Vale To whom reprint requests should be addressed. E-mail: vale@salk.edu. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.97.18.10277 |